Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Drug Safety|May 14, 2015
Methodological approaches to evaluate the impact of FDA drug safety communicationsAaron S Kesselheim, Eric G Campbell, Sebastian Schneeweiss, et al.
BMJ Mental Health|February 6, 2026
Risk of neutropenia-related hospitalisation among clozapine initiatorsAmeet Sarpatwari, Mufaddal Mahesri, Joyce Lii, et al.
Drug Safety|November 5, 2024
Teratogenic Risk Impact and Mitigation (TRIM): Study Protocol for the Development of a Decision Support Tool to Prioritize Medications for Risk MitigationAlmut G Winterstein, Celeste L Y Ewig, Yanning Wang, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|September 28, 2019
Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National SurveyAaron S Kesselheim, Michael S Sinha, Paula Rausch, et al.
Drug Safety|April 27, 2021
A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) ProgramsAmeet Sarpatwari, Mayookha Mitra-Majumdar, Katsiaryna Bykov, et al.
JAMA Network Open|July 18, 2024
Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for AmbrisentanWilliam B Feldman, Mufaddal Mahesri, Ameet Sarpatwari, et al.
Pharmacoepidemiology and Drug Safety|April 22, 2021
Validity of ICD-10-CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapiesVincent Lo Re, Dena M Carbonari, Jerry Jacob, et al.
Pageof 5